Floatz logo

Hycamtin

Malignant Solid Tumors

AstraZenecaPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

30 Active assets in the Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Peg-Rhg-Csf
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4B
DEXAMETHASONE
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Medroxyprogesterone acetate
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Zofran
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B

View all 38 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →